ECE2024 Poster Presentations Adrenal and Cardiovascular Endocrinology (95 abstracts)
Morning cortisol levels in patients with established primary adrenal insufficiency
Alessandro Prete 1,1 , Verena Theiler-Schwetz 1 , Wiebke Arlt 2 , Irina-Oana Chifu 3 , Birgit Harbeck 4,5 , Catherine Napier 6 , JohnD.C. Newell-Price 7 , Aled Rees 8 , Nicole Reisch 9 , GünterK. Stalla 10 , Naila Aslam 11 , Helen Coope 11 , Kerry Maltby 11 , John Porter 11 , Jo Quirke 11 & Richard John M. Ross 7
1University of Birmingham, UK; 2MRC Laboratory of Medical Sciences, UK; 3University Hospital Würzburg, Würzburg, Germany; 4University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 5amedes experts, Hamburg, Germany; 6Newcastle University, UK; 7The University of Sheffield, UK; 8Cardiff University, UK; 9Klinikum der Universität München, München, Germany; 10Ludwig Maximilian University of Munich, München, Germany; 11Diurnal, UK
Background: Primary adrenal insufficiency (PAI) is rare: prevalence ~100–140/million and incidence 4:1 000 000/year in Western societies 1. The diagnosis of PAI is suggested by an early-morning cortisol <140 nmol/l (5 μg/dl) 1. The commonest cause in adults is autoimmunity (~90% in Western countries) and it is generally considered progressive once the diagnosis is made, although it has been reported that residual cortisol secretion is present in ~30% of patients 2. We have developed a modified-release formulation of hydrocortisone to replace the physiological cortisol circadian rhythm and are undertaking a Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Modified-Release Hydrocortisones: Chronocort® Versus Plenadren®, in PAI. During recruitment, we were surprised by the number of patients who were ineligible as they had detectable morning cortisol levels.
Methods: Main inclusion criteria: Participants with known PAI on stable glucocorticoid replacement therapy and an early morning pre-dose cortisol <50 nmol/l (1.8 μg/dl). Baseline serum cortisol was taken at ~0700 h and measured in a central laboratory by ADVIA Centaur® immunoassay with the lower limit of detection <14 nmol/l (<0.5 μg/dl).
Results: 86 patients with PAI (autoimmune aetiology in 71), median age 52 years (range 20–73), 60 female, were screened in 8 centres in UK and Germany. 18 (21%) patients were excluded from the study based on morning cortisol >50 nmol/l (1.8 μg/dl), and of those 68 patients who qualified on the main inclusion criteria 51 (59% of screened) had a cortisol <14 nmol/l (<0.5 μg/dl). Of the 18 patients (autoimmune aetiology in 10) excluded based on their morning cortisol level, 9 (50%) were female and 11 (13% of screened), had morning cortisol ≥140 nmol/l (5.0 μ/dl). 12 patients with morning cortisol of >50 nmol/l (1.8 μ/dl) were retested and only 2 then qualified; their initial morning cortisol levels were 70 and 51 nmol/l. In patients retested the median difference between retest and the initial sample was 13 nmol/l (range 1–421 nmol/l).
Conclusions: In patients with an established diagnosis of PAI, the majority had undetectable morning cortisol, but cortisol was detectable in 41% of patients and above 140 nmol/l in 13% confirming previous publications 2. Retesting patients with a cortisol >50 nmol/l showed very similar results suggesting that the detectable cortisol was not an artefact and likely due to background cortisol secretion.
References: 1. Bornstein SR, et al. J Clin Endocrinol Metab 2016;101:364–89.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more